Ikervis (Ciclosporin)

Ciclosporin in Ikervis binds to cyclophilin inside ocular cells, forming a complex that inhibits calcineurin. This inhibition blocks the activation of T‑cells and the subsequent release of inflammatory cytokines, resulting in a localized anti‑inflammatory effect on the eye surface and reduction of ocular inflammation.

The dosing regimen for Ikervis is determined by the prescribing clinician based on the severity of the condition and patient response. Typically, one drop is instilled in the affected eye(s) once daily, but the exact frequency and duration are individualized and should follow the prescriber’s instructions.

The safety of Ikervis in pregnancy or while breastfeeding has not been definitively established. Because systemic absorption is possible, clinicians usually weigh potential benefits against unknown risks and may advise discontinuation unless the therapeutic advantage justifies continued use. Consultation with a healthcare professional is essential.

To order Ikervis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to Ikervis is lifitegrast (Xiidra), another prescription eye drop for dry eye disease. While both target ocular inflammation, lifitegrast blocks the LFA‑1/ICAM‑1 interaction, whereas Ikervis uses a calcineurin‑inhibiting mechanism. Clinical choice often depends on patient tolerance, response, and physician preference.

Ikervis should be stored at room temperature, below 25 °C, in its original packaging. Protect the emulsion from direct light and moisture, and keep the container tightly closed when not in use. Do not freeze the product, and discard any solution that appears discolored or contains particles.

Before instillation, wash hands thoroughly and avoid contaminating the dropper tip. Tilt the head back, gently pull down the lower eyelid, and place one drop into the conjunctival sac. Close the eye for a few seconds without blinking, then gently press the inner corner of the eye to reduce systemic absorption. Repeat for the other eye if prescribed.

Serious adverse events, although rare, include corneal ulceration, persistent intraocular inflammation, significant vision loss, and systemic allergic reactions such as swelling or rash. Patients should seek immediate medical attention if they notice worsening eye pain, sudden loss of vision, or signs of a severe allergic response.

Ikervis should not be used by individuals with a known hypersensitivity to ciclosporin or any of the formulation’s excipients. It is also contraindicated in eyes with active bacterial, viral, or fungal infections until the infection is adequately treated, and caution is advised in patients with uncontrolled glaucoma or severe ocular surface disease.